Google
CUBT Stock Price & Analysis — Curative Biotechnology Inc (Healthcare >> Biotechnology)
CUBT FAQ
What is CUBT's ROE?
Curative Biotechnology Inc reports a Return on Equity (ROE) of 33.87%.
What is CUBT's dividend yield?
Curative Biotechnology Inc offers a dividend yield of 0.00%.
What is CUBT's Quality Score?
Our AI rates CUBT's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CUBT?
Our AI Timing Score for CUBT is 3 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CUBT belong to?
Curative Biotechnology Inc is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange
CUBT AI Analysis Summary
Our AI summary for CUBT: Curative Biotechnology Inc (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 33.87%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 3/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.30
Price
0.27
(25.73%)
Day Change
|
|
|---|
CUBT, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.30 |
| PBV / Sector |
-1.60 / 44,105.10
|
| Earning Per Share | -0.28 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
711.886175000000
|
| Average 1W Daily Value |
1197.662400000000
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 07:59:50 |
| Symbol | CUBT |
| Name | CURATIVE BIOTECHNOLOGY INC |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 7.66 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 10.07 / 9,702.21 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3801 PGA Blvd, Palm Beach Gardens, FL, United States, 33410
Phone: 561 907 8990
Website: https://curativebiotech.com
Sector: Healthcare >> Biotechnology
Description: Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap